Introducing ByonGuard: Conditional Activation Technology that Improves the Safety Profile & Therapeutic Index of ADCs - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Introducing ByonGuard: Conditional Activation Technology that Improves the Safety Profile & Therapeutic Index of ADCs

10:30 am - Monday 12th October 2026

Demonstrating rationale to develop conditionally active ADCs to overcome challenges with target mediated toxicity and improve therapeutic index
Laying out ADC masking mechanism leveraging steric masking nanobody peptide activated by a variety of proteases in the tumor
Highlighting development of ADCs leveraging masking technology including preclinical efficacy and safety profiles

Speakers:

Wim Dokter

Wim Dokter

Chief Scientific Officer

Byondis B.V.